SCHEMBL4891611

SCHEMBL4891611

COc1cc(C(=O)Nc2ccc(Nc3nccc(-c4ccccn4)n3)cc2)cc(OC)c1OC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
PRKCA P17252 2/20 0.55
SYK P43405 2/20 0.55
SMN1; SMN2 Q16637 3/20 0.54
ALDH1A1 P00352 1/20 0.54
HPGD P15428 1/20 0.54
PRKD3 O94806 1/20 0.52
PRKCG P05129 1/20 0.52
PRKCB P05771 1/20 0.52
LCK P06239 1/20 0.52
PRKCH P24723 1/20 0.52
PRKCI P41743 1/20 0.52
ZAP70 P43403 1/20 0.52
PRKCE Q02156 1/20 0.52
PRKCQ Q04759 1/20 0.52
PRKCZ Q05513 1/20 0.52
PRKCD Q05655 1/20 0.52
PRKD1 Q15139 1/20 0.52
BTK Q06187 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4897577 0.89 ABL1 (0.60) PRKCABTKABCB1ABL1BCR
SCHEMBL4901565 0.88 MEN1 (0.59) MEN1KMT2APRKCASYKJAK2
SCHEMBL4901012 0.85 PRKCA (0.74) PRKCASMN1; SMN2ALDH1A1PRKD3PRKCG
SCHEMBL4903320 0.85 ABL1 (0.61) MEN1KMT2APRKCASMN1; SMN2ALDH1A1
SCHEMBL4892485 0.85 PRKCA (0.62) MEN1KMT2APRKCASYKSMN1; SMN2
SCHEMBL6980729 0.84 IGF1R (0.68) PRKCASYKPRKD3PRKCGPRKCB
SCHEMBL4903298 0.81 ABL1 (0.59) PRKCASYKSMN1; SMN2JAK2ABL1
SCHEMBL4900091 0.80 MEN1 (0.60) MEN1KMT2APRKCAPRKD3PRKCG
SCHEMBL4899630 0.80 ABL1 (0.64) MEN1KMT2APRKCASMN1; SMN2ALDH1A1
SCHEMBL4899326 0.79 PDGFRB (0.56) PRKCASYKPRKD3PRKCGPRKCB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US claimed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP claimed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO claimed
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US disclosed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP disclosed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080187575-A1 Pyrimidine Derivatives TYMP, TDP1, PNP MEN1 3644/4885KMT2A 3738/4885PRKCA 2607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.